A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Cetuximab; Ixabepilone
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2009 Actual patient number (54) added as reported by ClinicalTrials.gov.